Last reviewed · How we verify
A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life (Sched2)
The purpose of this study is: To assess whether there are differences in antibody persistence eight months post primary (pre-booster) or in responses to the booster with regard to the Meningococcal C Conjugate (MCC) vaccine given in infancy. To examine levels of diphtheria and tetanus antibody pre- and post-booster, with regard to the carrier proteins contained in the conjugate vaccines.
Details
| Lead sponsor | Public Health England |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 130 |
| Start date | 2008-02 |
| Completion | 2010-03 |
Conditions
- Meningococcal Infections
- Pneumococcal Infections
Interventions
- NeisVacC (Meningococcal C conjugate vaccine)
- Menjugate (Meningococcal C conjugate vaccine)
Countries
United Kingdom